1. Introduction {#sec1-ijms-17-00766}
===============

In recent years, the development of clean, safe and efficient eco-friendly protocols has become a major challenge in green chemistry. Ultrasound (US) has been extensively adopted as a promising green pathway \[[@B1-ijms-17-00766]\] in several organic transformations. US was reported to drastically increase reaction rates, improve yields and provide high purity of products with an easy work-up \[[@B2-ijms-17-00766],[@B3-ijms-17-00766],[@B4-ijms-17-00766]\]. An enhanced selectivity and reduction of chemical hazards using this safe ultrasound method have been well documented \[[@B2-ijms-17-00766],[@B3-ijms-17-00766],[@B4-ijms-17-00766]\].

Ionic liquids (ILs) have emerged as fascinating new green solvents as alternatives to volatile organic solvents due to their sought-after properties such as negligible vapor pressure, high thermal stability, high ionic conductivity and high ability to solvate both polar and non-polar compounds \[[@B2-ijms-17-00766],[@B5-ijms-17-00766]\]. Their most attractive features are their very low volatility, nonflammability and stability, which make them suitable for applications in diverse fields, such as organic synthesis, catalysis and biocatalysis, analytical chemistry, nanotechnology, food science and as function fluids (e.g., lubricants, heat transfer fluids and corrosion inhibitors) \[[@B4-ijms-17-00766],[@B5-ijms-17-00766]\]. Recently, some acidic task-specific ILs were used as solvents and catalysts for the hydrolysis/conversion of cellulose and lignocellulosic biomass \[[@B6-ijms-17-00766]\].

ILs have also demonstrated promising applications for medicinal chemistry, including antimicrobial, antiseptic, anticancer and anti-inflammatory activities \[[@B7-ijms-17-00766]\].

Because the synthesis of ionic liquids \[[@B5-ijms-17-00766],[@B8-ijms-17-00766]\] is not easy, chemists have developed several green protocols for the clean and safe synthesis of IL liquids including microwave (MW), ultrasound (US) and solvent-free reactions.

Hydrazones are an important class of Schiff bases and are widely used as antimalarial \[[@B9-ijms-17-00766]\], anticancer \[[@B10-ijms-17-00766]\], antibacterial \[[@B11-ijms-17-00766]\], antifungal \[[@B12-ijms-17-00766]\], antitubercular \[[@B13-ijms-17-00766]\], antimicrobial \[[@B14-ijms-17-00766]\] and antiviral \[[@B15-ijms-17-00766]\] agents. The azomethine linkage on the Schiff base structures are responsible for their bioactivity, enabling them to serve as models for biologically important scaffolds \[[@B16-ijms-17-00766]\]. In addition, there are many commonly used drugs incorporating hydrazone groups in their structures.

In view of the emerging importance of ILs and hydrazones as antimicrobial and anticancer agents and our general interest in ultrasound-assisted organic synthesis, we focus on developing a straightforward, safe and ecofriendly method for the synthesis of fluorinated pyridinium ILs tethering a hydrazone linkage under ultrasound irradiation and conventional heating. To the best of our knowledge, the synthesis of ionic liquids carrying a hydrazone functionality has not been previously reported in the literature. However, the synthesized compounds were found to be salts rather than ILs and were screened for their antimicrobial and antitumor activities in order to evaluate the synergistic effect resulting from the clubbing of these salts with azomethine hydrazone functionality in a single molecular frame work.

2. Results and Discussion {#sec2-ijms-17-00766}
=========================

2.1. Chemistry {#sec2dot1-ijms-17-00766}
--------------

In the present work, several attempts to find the optimum conditions for the synthesis of new classes of fluorinated pyridinium ionic liquid-based hydrazone have been investigated under both conventional and ultrasound methods. These attempts led to the finding that the alkylation of isonicotinic acid hydrazide with several alkyl iodides in different solvents such as acetonitrile, toluene and methanol afforded very poor yields (24%--28%) of compound **4**, under either conventional heating or US. In addition, no reaction was observed under several attempts to condensate the resulting **4** with *p*-fluorobenzaldehyde (**2**) in the presence of a catalytic amount of HCl in boiling ethanol and/or under ultrasonic conditions ([Scheme 1](#ijms-17-00766-sch001){ref-type="scheme"}).

Conversely, the successful strategy for synthesizing the target **5**--**10** was based on the alkylation of *N*-(4-fluorobenzylidene)isonicotinohydrazide (**3**) with the appropriate alkyl halides under both conventional and US conditions. Thus, the condensation of acid hydrazide **1** with *p*-fluorobenzaldehyde (**2**) afforded the corresponding hydrazone **3** in excellent yield (90%) in refluxing ethanol for 1 h; a comparable yield has been obtained within 30 min under ultrasound irradiation. The resulting hydrazone **3** has been alkylated with different alkyl iodides, furnishing the target halogenated pyridinium salts **5**--**10** in 83%--91% yields, as shown in [Scheme 1](#ijms-17-00766-sch001){ref-type="scheme"}.

When the alkylation was carried out under ultrasound irradiation, great reductions in reaction time (12--14 h) were observed with higher yields (90%--94%) compared to those obtained under the classical method (72 h) ([Table 1](#ijms-17-00766-t001){ref-type="table"}).

The structures of the hydrazones **5**--**10** have been established based on their mass and spectroscopic data (^1^H NMR, ^13^C NMR, ^19^F NMR). The NMR spectra of the synthesized compounds **5**--**10** measured in DMSO-*d*~6~ revealed the presence of a diastereomeric mixture (*i.e.*, *E*/*cis* and *E*/*trans*) for each imino-amide moiety.

The *N*-hexyl derivative **9** was selected to discuss the NMR data used to confirm the success of the quaternization reaction. From its ^1^H NMR spectrum, the appearance of the diagnostic C**H~3~** and NC**H~2~** as a triplet at δ~H~ 0.88 ppm and a doublet of doublets at δ~H~ 4.70 ppm, respectively, are clear evidence for the success of the alkylation reaction. The remaining methylene groups were also observed.

The spectrum also revealed the presence of two singlets at δ~H~ 8.16 and 8.50 ppm, with a ratio of 1:3, which have a total integration of one proton characteristic of the imine proton (**H**C=N). In addition, the N**H** group split into two singlets at δ~H~ 12.47 and 12.52 ppm that have a total integration of one proton with the same ratio ([Figure 1](#ijms-17-00766-f001){ref-type="fig"}). Moreover, eight aromatic protons resonated in their appropriate chemical shifts with a similar isomeric pattern to that observed for the NH and H--C=N groups. To confirm the solvent effect for the isomerism of hydrazones, the ^1^H NMR spectrum of compound **9** was recorded in a less polar solvent (CDCl~3~). Consequently, one singlet signal was observed at δ~H~ 12.25 ppm for the N**H** proton and at δ~H~ 9.13 ppm for the **H**C=N proton, corresponding to the *cis* and *trans* conformers of the *E* isomer ([Figure 2](#ijms-17-00766-f002){ref-type="fig"}). These results agree with those previously reported in our work, where the hydrazone functionality was proven to exhibit *E*/*cis* and *E*/*trans* geometrical isomerism in polar solvents such as DMSO-*d*~6~, while only the *E*/*cis* or *E*/*trans* isomer was recorded in a less polar solvent (CDCl~3~) \[[@B17-ijms-17-00766],[@B18-ijms-17-00766]\].

Further assignment of the diastereomer formation for compound **9** was supported by ^13^C NMR and dept-135 experiments. In the ^13^C NMR spectrum, each peak of compound **9** appeared as two sets of signals due to the presence of the diastereomeric mixture. In the aliphatic region, the methyl and N**C**H~2~ carbons resonated as two sets of signals at 61.43 and 61.51, respectively. The **C**=N and **C**=O groups of the *E*/*cis* and *E*/*trans* diastereomers also resonated as double peaks at δ~C~ 159.27--165.72 ppm.

The ^19^F NMR spectrum ([Figure 3](#ijms-17-00766-f003){ref-type="fig"}) also proved the formation of a diastereomeric mixture (*E*/*cis* and *E*/*trans*) through the appearance of two characteristic multiplets at δ~F~ −109.90 to −109.82 and −109.44 to −109.36 ppm, attributed to the aromatic fluorine atom.

The structure of compound **9** was also confirmed by the electron impact mass spectrum, which showed a molecular ion peak at 459.38 \[M^+^\].

All the newly synthesized iodonated pyridinium salts **5**--**10** have been subjected to a metathesis reaction in which the iodide anion has been displaced by different anions. The anion exchange reactions were carried out by their refluxing with different metal salts such as NaBF~4~, KPF~6~, NaOCOCF~3~, NaSCN, or NaNO~3~, in acetonitrile as solvent for 16 h to give new specific-based hydrazones **11**--**40** in 80%--98% yields ([Scheme 2](#ijms-17-00766-sch002){ref-type="scheme"}).

When these reactions were assisted by ultrasound irradiation, 6 h were required to afford comparable yields of the same ILs ([Table 2](#ijms-17-00766-t002){ref-type="table"}).

The analysis of the NMR spectra of compounds **11**--**40** revealed that their ^1^H and ^13^C NMR are practically the same as those recorded for their precursors **5**--**10**, with the isomeric splitting pattern. Accordingly, the ^31^P NMR, ^19^F NMR and mass spectra analyses have supported the success of the metathesis reaction. In the ^31^P NMR spectrum of compound **31**, the appearance of a characteristic multiplet signal at δ~P~ −157.37 to −131.02 ppm confirms the presence of the **P**F~6~^−^ anion. In addition, its ^19^F NMR spectrum displays two characteristic singlets at δ~F~ −71.10 and −69.22 ppm, confirming the presence of a fluorine atom in its P**F**~6~^−^ form, while the aromatic fluorine atom was assigned as two multiplets at δ~F~ (−109.90 to −109.82) ppm and (−109.44 to −109.36) ppm. In addition, the presence of a molecular ion peak at 473.39 \[M^+^\] in its mass spectrum supports the structure of compound **31**. The iodide anion exchange of **9** using NaBF~4~ as a metal salt led to the formation of compound **32**, with its structure supported by its ^11^B NMR and ^19^F NMR spectra. The appearance of a characteristic doublet at δ~B~ −1.28 ppm in the ^11^B NMR spectrum confirmed the incorporation of the boron anion in its structure.

The ^19^F NMR spectrum displays two doublets at δ~F~ −148.30 and −145.25 ppm, attributed to the fluorine anion (BF~4~^−^), while the aromatic fluorine was recorded at δ~F~ −109.90 to −109.82 ppm and −109.45 to −109.37 ppm as two multiplets. The structure of IL **32** has also been established based on its electron impact mass spectrum, which shows a molecular ion peak at 415.22 \[M^+^\]. The anion exchange with trifluoroacetate has also been investigated and gave IL **33**, as was also confirmed by its ^19^F NMR spectrum, which clearly shows a singlet at δ~F~ −73.50 ppm due to the CF~3~COO^−^ anion. The aromatic fluorine atom resonated at the expected area. The mass spectral data reveals the presence of the molecular ion peak at 441.18 \[M^+^\] as evidence for the formation of compound **33**.

Because **34** and **35** carrying NO~3~^−^ and/or SCN^−^ anion head-groups display similar ^1^H and ^13^C NMR spectra compared to their precursor **9**, their formation becomes more evident based on their mass spectra. The mass spectra of compounds **34** and **35** display molecular ion peaks at 390.37 \[M^+^\] and 386.56 \[M^+^\], respectively.

2.2. Biological Assay {#sec2dot2-ijms-17-00766}
---------------------

### 2.2.1. Antimicrobial Activity {#sec2dot2dot1-ijms-17-00766}

Compounds **5**--**15**, **21**--**25** and **31**--**40** were assessed *in vitro* for their efficacy as antimicrobial agents by the minimum inhibitory concentration (MIC) using the broth dilution method \[[@B19-ijms-17-00766],[@B20-ijms-17-00766]\] against six standard bacterial strains (*Streptococcus pneumonia*, *Bacillus subtilis*, *Staphylococcus aureus*, *Pseudomonas aeuroginosa*, *Escherichia coli* and *Klebsiella pneumonia*) and two fungi (*Aspergillus fumigatus* and *Candida albicans*). The MIC results are summarized in [Table 3](#ijms-17-00766-t003){ref-type="table"}.

The antibacterial activity screening for the halogenated pyridinium salts **5**--**10** against all of the bacterial strains demonstrated that all the compounds reveal promising antibacterial activities, with an MIC range of 8--16 µg/mL. In contrast, the opposite result was observed for the two fungal species, towards which the compounds showed no activity.

From the antibacterial activity results of compounds **11**--**40**, it can be stated that those resulting from the metathetical anion exchange with fluorinated metal salts (PF~6~^−^, BF~4~^−^ or CF~3~COO^−^) are more effective against all bacterial strains at an MIC of 4--8 µg/mL.

The antifungal bioassay results summarized in [Table 3](#ijms-17-00766-t003){ref-type="table"} reveal that, among the tested salts **11**--**40**, compounds **21**--**23**, **31**--**33** and **36**--**38** show good to excellent potency against all of the tested fungal strains, with an MIC range of 8--16 µg/mL. In fact, the highest antifungal activity, with an MIC of 8 µg/mL, was exhibited by compounds **33** and **38**, possessing a CF~3~COO^−^ counter anion and a C~6~ to C~7~ alkyl chain in the cation head group.

The antimicrobial activity and structure activity relationship reveal that the promising activity displayed by the halogenated **5**--**10** against all of the bacterial strains is presumably due to the chain length. The incorporation of a fluorine atom was found to dramatically increase the antimicrobial activity, as exhibited by the fluorinated **11**--**13**, **21**--**23**, **31**--**33** and **36**--**38** carrying PF~6~^−^, BF~4~^−^ and/or CF~3~COO^−^. In addition, the metathetic exchange with these fluorinated metal salts resulted in higher antifungal activity.

In the antimicrobial screening, it was observed that compounds with long alkyl side chains possessing a fluorine atom in their anion head-group (PF~6~^−^, BF~4~^−^ and CF~3~COO^−^) exhibit excellent activity compared to the corresponding halogenated precursors against all of the bacterial strains, indicating the influence of the presence of the fluorine atom in the structure of the ionic liquids.

### 2.2.2. Antiproliferative Activity {#sec2dot2dot2-ijms-17-00766}

An *in vitro* evaluation of the antiproliferative activities of the newly synthesized compounds was investigated against four human tumor cell lines by using the protocol described in ISO 10993-5 \[[@B21-ijms-17-00766]\]. The results are presented as IC~50~ ± SD values ([Table 4](#ijms-17-00766-t004){ref-type="table"}). Each experiment was repeated three times. IC~50~ concentrations were obtained from the dose--response curves using Graph Pad Prism Software 5.

Only the compounds shown in [Table 4](#ijms-17-00766-t004){ref-type="table"} demonstrated a measurable IC~50~ against the tested cancer cell lines and thus can be used as model compounds for the construction of novel anticancer drugs. Interestingly, reducing the chain length of the compounds yielded more potent cytotoxic activities, suggesting a steric factor mediating either transport or molecular interaction with the cellular targets.

3. Experimental Section {#sec3-ijms-17-00766}
=======================

3.1. General {#sec3dot1-ijms-17-00766}
------------

Melting points were recorded on a Stuart Scientific SMP1 apparatus (Stuart, Red Hill, UK) and are uncorrected. The IR spectra were recorded using an SHIMADZU FTIR-8400S spectrometer (SHIMADZU, Boston, MA, USA). The NMR spectra were measured with a Bruker spectrometer (400 and 600 MHz, Brucker, Fällanden, Switzerland) using Tetramethylsilane (TMS) (0.00 ppm) as an internal standard. The ESI and EI mass spectra were measured by Finnigan LCQ and Finnigan MAT 95XL spectrometers (Finnigan, Darmstadt, Germany), respectively. Ultrasound-assisted reactions were performed in a Kunshan KQ-250B ultrasound cleaner (50 KHz, 240 W, Kunshan Ultrasonic Instrument, Kunshan, China).

3.2. Synthesis and Characterization of N-(4-Fluorobenzylidene) Isonicotinohydrazide (**3**) {#sec3dot2-ijms-17-00766}
-------------------------------------------------------------------------------------------

### 3.2.1. Conventional Method {#sec3dot2dot1-ijms-17-00766}

A mixture of isonicotinic acid hydrazide (**1**) (1 mmol) in ethanol (25 mL) and 4-fluorobenzaldehyde (**2**) (1.2 mmol) with three drops of hydrochloric acid was refluxed for 1 h. After cooling, the excess solvent was removed under reduced pressure. The product formed was collected and crystallized from ethyl acetate to furnish the desired compound **3** mp: 214--215 °C (Lit. mp: 216--220 °C) \[[@B22-ijms-17-00766]\]. ^1^H NMR (600 MHz, DMSO-*d*~6~): δ~H~ = 7.27 (dd, 0.25H, *J* = 6 Hz, 12 Hz, Ar--**H**), 7.35 (dd, 1.75H, *J* = 6 Hz, 12 Hz, Ar--**H**), 7.59 (t, 0.25H, *J* = 6 Hz, Ar--**H**), 7.67 (d, 0.25H, *J* = 6 Hz, Ar--**H**), 7.82--7.84 (m, 3.5H, *J* = 6 Hz, Ar--**H**), 8.11 (s, 0.1H, **H**--C=N), 8.48 (s, 0.9H, **H**--C=N), 8.75 (d, 0.25H, *J* = 6 Hz, Ar--**H**), 8.81 (d, 1.75H, *J* = 6 Hz, Ar--**H**), 12.04 (s, 0.2H, CON**H**), 12.09 (s, 0.8H, CON**H**). ^13^C NMR (150 MHz, DMSO-*d*~6~): δ~C~ = 116.38, 116.53, 121.98, 123.53, 129.92, 129.98, 131.12, 140.89, 148.34, 150.02, 150.81 (Ar--**C**), 162.08, 162.94, 164.58 (**C**=N, **C**=O).

### 3.2.2. Ultrasound Method {#sec3dot2dot2-ijms-17-00766}

A mixture of isonicotinic acid hydrazide (**1**) (1 mmol) in ethanol (25 mL) and 4-fluorobenzaldehyde (**2**) (1.2 mmol) with a few drops of hydrochloric acid was irradiated by ultrasound irradiation for 30 min at room temperature. The reaction proceeded as described above to furnish the same compound **3**.

3.3. General Procedures for the Synthesis of Pyridinium Tagged Hydrazones **5**--**10** {#sec3dot3-ijms-17-00766}
---------------------------------------------------------------------------------------

### 3.3.1. Conventional Method {#sec3dot3dot1-ijms-17-00766}

A mixture of compound **3** (1 mmol) and the appropriate alkyl iodide with chain lengths ranging from C~2~ to C~7~ (1.5 mmol) in acetonitrile (30 mL) was refluxed for 72 h. After cooling, the solvent was removed under reduced pressure, and the solid formed was collected by filtration, washed with acetonitrile, and crystallized from dichloromethane to afford the desired pyridinium hydrazones **5**--**10**.

### 3.3.2. Ultrasound Method {#sec3dot3dot2-ijms-17-00766}

A mixture of compound **1** (1 mmol) and the appropriate alkyl iodide with chain lengths ranging from C~2~ to C~7~ (1.5 mmol) in acetonitrile (30 mL) was irradiated by ultrasound irradiation at room temperature. The reaction proceeded as described above to afford the desired pyridinium hydrazones **5**--**10**.

*1-Ethyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridinium iodide* (***5***). It was obtained as yellow crystals; mp: 223--224 °C. FT-IR (KBr), cm^−1^: $\overline{V}$ = 1613 (C=N), 1690 (C=O), 2893, 2960 (Al--H), 3075 (Ar--H). ^1^H NMR (600 MHz, DMSO-*d*~6~): δ~H~ = 1.58--1.63 (m, 3H, C**H**~3~), 4.70--4.75 (m, 2H, NC**H**~2~), 7.26 (dd, 0.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 7.37 (dd, 1.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 8.17 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 6 Hz, Ar--**H**), 8.51 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 6 Hz, Ar--**H**), 9.26 (d, 0.5H, *J* = 6 Hz, Ar--**H**), 9.35 (d, 1.5H, *J* = 6 Hz, Ar--**H**), 12.48 (s, 0.8H, CON**H**), 12.51 (s, 0.2H, CON**H**).^13^C NMR (150 MHz, DMSO-*d*~6~): δ~C~ = 16.59, 16.72 (**C**H~3~), 57.07, 57.16 (N**C**H~2~), 116.32, 116.46, 116.51, 116.65, 126.60, 127.62, 129.91, 129.97, 130.24, 130.30, 130.50, 130.70, 130.71, 145.36, 145.62, 146.01, 147.75, 149.84, 149.99 (Ar--**C**), 159.26, 162.86, 163.18, 164.83, 165.70 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.81), (−109.43 to −109.35) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 399.36 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-propylpyridinium iodide* (***6***). It was obtained as yellow crystals; mp: 186--187 °C. FT-IR (KBr), cm^−1^: $\overline{V}$ = 1615 (C=N), 1689 (C=O), 2890, 2955 (Al--H), 3065 (Ar--H). ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.90--0.95 (m, 3H, C**H**~3~), 1.95--2.04 (m, 2H, NCH~2~C**H**~2~), 4.68 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.27 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.38 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.41 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 8.51 (s, 0.75H, **H**--C=N), 8.55 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.34 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.49 (s, 0.75H, CON**H**), 12.53 (s, 0.25H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 9.27, 9.30 (**C**H~3~), 23.11, 23.19 (NCH~2~**C**H~2~), 61.30, 61.38 (N**C**H~2~), 114.86, 115.06, 115.27, 125.22, 126.18, 128.43, 128.52, 128.81, 128.90, 129.11, 129.26, 129.29, 144.14, 144.78, 146.41, 148.39, 148.72 (Ar--**C**), 157.85, 161.35, 163.82, 164.30 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.83), (−109.41 to −109.33) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 413.35 \[M^+^\].

*1-Butyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridinium iodide* (***7***). It was obtained as yellow crystals; mp: 184--185 °C. FT-IR (KBr), cm^−1^: $\overline{V}$ = 1620 (C=N), 1687 (C=O), 2882, 2961 (Al--H), 3071 (Ar--H). ^1^H NMR (600 MHz, DMSO-*d*~6~): δ~H~ = 0.93--0.96 (m, 3H, C**H**~3~), 1.30--1.38 (m, 2H, C**H**~2~CH~3~), 1.93--2.00 (m, 2H, NCH~2~C**H**~2~), 4.71 (dd, 2H, *J* = 6 Hz, 12 Hz, NC**H**~2~), 7.26 (dd, 0.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 7.37 (dd, 1.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 6 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 6 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 6 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 6 Hz, Ar--**H**), 12.48 (bs, 1H, CON**H**). ^13^C NMR (150 MHz, DMSO-*d*~6~): δ~C~ = 13.79, 13.81 (**C**H~3~), 19.23, 19.30 (**C**H~2~CH~3~), 32.99, 33.08 (NCH~2~**C**H~2~), 61.22, 61.29 (N**C**H~2~), 116.31, 116.46, 116.51, 116.65, 126.65, 127.62, 129.86, 129.92, 130.24, 130.30, 130.54, 130.72, 145.58, 146.19, 147.82, 149.82 (Ar--**C**), 159.26, 163.19, 164.84, 165.71 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.88 to −109.84), (−109.41 to −109.33) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 427.28 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-pentylpyridinium iodide* (***8***). It was obtained as yellow crystals; mp: 216--217 °C. FT-IR (KBr), cm^−1^: $\overline{V}$ = 1622 (C=N), 1682 (C=O), 2891, 2970 (Al--H), 3070 (Ar--H). ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.86--0.90 (m, 3H, C**H**~3~), 1.25--1.37 (m, 4H, 2×C**H**~2~), 1.93--2.02 (m, 2H, NCH~2~C**H**~2~), 4.68 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.23 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.37 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.15 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.34 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.47 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.70, 13.71 (**C**H~3~), 21.51, 27.47, 27.55 (2×***C***H~2~), 30.20, 30.31 (NCH~2~**C**H~2~), 60.91, 60.99 (N**C**H~2~), 115.76, 115.97, 116.18, 126.15, 127.11, 129.35, 129.44, 129.73, 129.82, 130.20, 130.23, 145.08, 145.68, 147.33, 149.33, 149.63 (Ar--**C**), 158.76, 162.28, 164.75, 165.22 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.81), (−109.41 to −109.34) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 441.10 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-hexylpyridinium iodide* (***9***). It was obtained as yellow crystals; mp: 227--228 °C. FT-IR (KBr), cm^−1^: $\overline{V}$ = 1625 (C=N), 1695 (C=O), 2883, 2975 (Al--H), 3080 (Ar--H). ^1^H NMR (600 MHz, DMSO-*d*~6~): δ~H~ = 0.88 (t, 3H, *J* = 6 Hz, C**H**~3~), 1.29--1.33 (m, 6H, 3×C**H**~2~), 1.95--1.97 (m, 2H, NCH~2~C**H**~2~), 4.70 (dd, 2H, *J* = 6 Hz, 12 Hz, NC**H**~2~), 7.25 (dd, 0.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 7.37 (dd, 1.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 6 Hz, 12 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 6 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 6 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 6 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 6 Hz, Ar--**H**), 12.47 (s, 0.75H, CON**H**), 12.52 (s, 0.25H, CON**H**). ^13^C NMR (150 MHz, DMSO-*d*~6~): δ~C~ = 14.28, 14.30 (**C**H~3~), 22.32, 25.52, 25.55 (3×**C**H~2~), 31.01, 31.09 (NCH~2~**C**H~2~), 61.43, 61.51 (N**C**H~2~), 116.29, 116.44, 116.51, 116.65, 126.13, 126.65, 127.62, 129.86, 129.91, 130.24, 130.30, 130.70, 130.71, 145.56, 146.18, 147.82, 149.82 (Ar--**C**), 159.27, 163.19, 164.84, 165.72 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.90 to −109.82), (−109.44 to −109.36) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 455.38 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-heptylpyridinium iodide* (***10***). It was obtained as yellow crystals; mp: 218--219 °C. FT-IR (KBr), cm^−1^: $\overline{V}$ = 1628 (C=N), 1688 (C=O), 2894, 2962 (Al--H), 3075 (A--H). ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.84--0.88 (m, 3H, C**H**~3~), 1.23--1.31 (m, 8H, 4×C**H**~2~), 1.94--2.00 (m, 2H, NCH~2~C**H**~2~), 4.70 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.22 (t, 0.5H, *J* = 8 Hz, A--**H**), 7.34 (t, 1.5H, *J* = 8 Hz, A--**H**), 7.62 (dd, 0.5H, *J* = 8 Hz, 12 Hz, A--**H**), 7.88 (dd, 1.5H, *J* = 4 Hz, 8 Hz, A--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.34 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.47 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.86 (**C**H~3~), 21.91, 25.31, 25.36, 27.99, 30.51, 30.63, 30.95, 30.98 (5×**C**H~2~), 60.94, 61.01 (N**C**H~2~), 115.75, 115.95, 116.17, 126.14, 127.11, 129.36, 129.45, 129.72, 129.81, 130.06, 130.21, 130.24, 145.09, 145.67, 147.34, 149.36, 149.63 (Ar--**C**), 158.76, 162.27, 164.75, 165.20 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.93 to −109.85), (−109.43 to −109.35) (2m, 1F, Ar--**F**). MS (ESI) *m/z* = 469.42 \[M^+^\].

3.4. General Metathesis Procedure for the Synthesis of Specific **11--40** {#sec3dot4-ijms-17-00766}
--------------------------------------------------------------------------

### 3.4.1. Conventional Method {#sec3dot4dot1-ijms-17-00766}

A mixture of compounds **5**--**10** (1 mmol) in acetonitrile (8 mL) and potassium hexafluorophosphate, sodium tetrafluoroborate, sodium nitrate, sodium thiocyanate and/or sodium trifluoroacetate (1.2 mmol) was heated under reflux for 16 h. After cooling, the solid formed was filtered and washed with water and/or chloroform to give the desired compounds **11**--**40**.

### 3.4.2. Ultrasound Method {#sec3dot4dot2-ijms-17-00766}

A mixture of compounds **5**--**10** (1 mmol) in acetonitrile (8 mL) and potassium hexafluorophosphate, sodium tetrafluoroborate, sodium nitrate, sodium thiocyanate and/or sodium trifluoroacetate (1.2 mmol) was irradiated by ultrasound irradiation for 5--6 h at room temperature. The reaction proceeded as described above to afford the same compounds **11**--**40**.

*1-Ethyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridinium hexafluorophosphate* (***11***). It was obtained as yellow crystals; mp: 175--176 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 1.57--1.63 (m, 3H, C**H**~3~), 4.69--4.74 (q, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.24 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.24 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.49 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 16.00, 16.12 (**C**H~3~), 56.51, 56.61 (N**C**H~2~), 115.71, 115.89, 116.11, 126.05, 127.08, 129.32, 129.41, 129.66, 129.74, 129.98, 130.16, 130.19, 144.79, 145.09, 145.43, 147.27, 149.32, 149.46 (Ar--**C**), 158.72, 161.91, 162.22, 164.69, 165.13 (**C**=N, **C**=O). ^31^P NMR (162 MHz, DMSO-*d*~6~): δ~P~ = −157.37 to −131.03 (m, 1P, **P**F~6~). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = −71.09, −69.20 (2s, 6F, P**F~6~**), (−109.89 to −109.81), (−109.43 to −109.35) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 417.95 \[M^+^\].

*1-Ethyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridinium tetrafluoroborate* (***12***). It was obtained as yellow crystals; mp: 205--206 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 1.57--1.63 (m, 3H, C**H**~3~), 4.69--4.74 (q, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.24 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.24 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.48 (s, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 16.06, 16.19 (**C**H~3~), 56.57, 56.67 (N**C**H~2~), 115.77, 115.96, 116.18, 126.11, 127.13, 129.39, 129.47, 129.72, 129.81, 130.04, 130.21, 130.24, 144.86, 145.14, 145.50, 147.30, 149.37, 149.51 (Ar--**C**), 158.77, 162.28, 164.76, 165.20 (**C**=N, **C**=O). ^11^B NMR (128 MHz, DMSO-*d*~6~): δ~B~ = −1.29 (d, 1B, **B**F~4~). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.85 to −109.82), (−109.42 to −109.34) (2m, 1F, Ar--**F**), −148.28, −148.29 (2d, 4F, B**F**~4~). MS (ES) *m*/*z* = 359.46 \[M^+^\].

*1-Ethyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridinium trifluoroacetate* (***13***). It was obtained as yellow crystals; mp: 211--212 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 1.57--1.63 (m, 3H, C**H**~3~), 4.69--4.75 (q, 2H, *J* = 8 Hz, 12 Hz, NC**H**~2~), 7.27 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.51 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.34 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.49 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 16.00, 16.13 (**C**H~3~), 56.50, 56.59 (N**C**H~2~), 115.71, 115.89, 116.11, 126.03, 127.06, 129.33, 129.41, 129.64, 129.73, 129.97, 130.16, 130.19, 144.80, 145.07, 145.42, 147.29, 149.30, 149.44 (Ar--**C**), 158.73, 161.89, 162.20, 164.67, 165.12 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = −73.49 (s, 3F, C**F~3~**), (−109.89 to −109.82), (−109.45 to −109.37) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 385.22 \[M^+^\].

*1-Ethyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridinium nitrate* (***14***). It was obtained as yellow crystals; mp: 210--211 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 1.57--1.63 (m, 3H, C**H**~3~), 4.69--4.74 (q, 2H, *J* = 8 Hz, 12 Hz, NC**H**~2~), 7.24 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.51 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.34 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 12.49 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 16.00, 16.13 (**C**H~3~), 56.50, 56.59 (N**C**H~2~), 115.71, 115.89, 116.11, 126.03, 127.06, 129.33, 129.41, 126.65, 129.73, 129.97, 130.16, 130.19, 144.81, 145.08, 145.46, 147.24, 149.30, 149.44 (Ar--**C**), 158.72, 161.89, 162.21, 164.36, 164.68, 165.13 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.81), (−109.43 to −109.35) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 334.37 \[M^+^\].

*1-Ethyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridinium thiocyanate* (***15***). It was obtained as yellow crystals; mp: 203--205 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 1.58--1.63 (m, 3H, C**H**~3~), 4.69--4.75 (q, 2H, *J* = 8 Hz, 12 Hz, NC**H**~2~), 7.24 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.24 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.49 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 16.01, 16.12 (**C**H~3~), 56.52, 56.62 (N**C**H~2~), 115.70, 115.89, 116.11, 126.04, 127.07, 129.32, 129.40, 129.50, 129.65, 129.74, 129.95, 130.15, 130.18, 144.79, 145.09, 145.44, 147.24, 149.31, 149.45 (Ar--**C**), 158.72, 162.21, 164.69, 165.12 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~) δ~F~ = (−109.89 to −109.81), (−109.43 to −109.35) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 330.17 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-propylpyridinium hexafluorophosphate* (***16***). It was obtained as yellow crystals; mp: 180--181 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.89--0.95 (m, 3H, C**H**~3~), 1.94--2.05 (m, 2H, NCH~2~C**H**~2~), 4.67 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.26 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.37 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.41 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.24 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.47 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 11.16, 11.19 (**C**H~3~), 25.00, 25.08 (NCH~2~***C***H~2~), 63.22, 63.30 (N**C**H~2~), 116.75, 116.94, 117.16, 127.13, 128.09, 130.33, 130.41, 130.71, 130.79, 130.99, 131.18, 131.21, 146.06, 146.67, 148.34, 150.32, 150.64 (Ar--**C**), 159.75, 163.26, 165.73, 166.19 (**C**=N, **C**=O).^31^P NMR (162 MHz, DMSO-*d*~6~): δ~P~ = −152.98 to −135.42 (m, 1P, **P**F~6~). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = −71.08, −69.19, (2s, 6F, P**F~6~**), (−109.89 to −109.83), (−109.41 to −109.33) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 431.37 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-propylpyridinium tetrafluoroborate* (***17***). It was obtained as yellow crystals; mp: 162--163 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.90--0.95 (m, 3H, C**H**~3~), 1.94--2.05 (m, 2H, NCH~2~C**H**~2~), 4.65 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.26 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.41 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.23 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.31 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 12.46 (s, 0.75H, CON**H**), 12.50 (s, 0.25H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 10.18 (**C**H~3~), 24.02, 24.10 (NCH~2~***C***H~2~), 62.26, 62.35 (N**C**H~2~), 115.77, 115.96, 116.18, 126.15, 127.12, 129.34, 129.43, 129.73, 129.82, 130.05, 130.20, 130.23, 145.10, 145.69, 147.39, 149.36 (Ar--**C**), 158.78, 162.29, 164.76, 165.21 (**C**=N, **C**=O). ^11^B NMR (128 MHz, DMSO-*d*~6~): δ~B~ = −1.29 (d, 1B, **B**F~4~). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.80), (−109.41 to −109.33) (2m, 1F, Ar--**F**); −148.29, −148.24 (2d, 4F, B**F**~4~). MS (ESI) *m*/*z* = 373.49 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-propylpyridinium trifluoroacetate* (***18***). It was obtained as yellow crystals; mp: 151--152 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ =0.89--0.95 (m, 3H, C**H**~3~), 1.94--2.03 (m, 2H, NCH~2~C**H**~2~), 4.65 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.24 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.38 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.41 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.24 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.50 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 10.12, 10.15 (**C**H~3~), 23.97, 24.06 (NCH~2~***C***H~2~), 62.15, 62.24 (N**C**H~2~), 115.71, 115.90, 116.12, 126.08, 127.04, 129.27, 129.36, 129.66, 129.74, 129.97, 130.15, 144.99, 145.62, 147.29, 149.23 (Ar--**C**), 158.71, 162.21, 165.17 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = −73.47 (s, 3F, C**F~3~**), (−109.87 to −109.79), (−109.40 to −109.31) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 399.00 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-propylpyridinium nitrate* (***19***). It was obtained as yellow crystals; mp: 172--173 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.90--0.95 (m, 3H, C**H**~3~), 1.94--2.05 (m, 2H, NCH~2~C**H**~2~), 4.69 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.25 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.36 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.52 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.26 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.35 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 12.45 (ds, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 8.49 (**C**H~3~), 22.31, 22.41 (NCH~2~***C***H~2~), 60.58, 60.64 (N**C**H~2~), 114.08, 114.26, 114.48, 124.45, 125.43, 127.69, 127.78, 128.04, 128.13, 128.35, 128.51, 128.54, 143.38, 143.43, 14.00, 145.65, 147.72, 147.96 (Ar--**C**), 157.06, 160.26, 160.59, 162.73, 163.06, 163.46 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.80), (−109.41 to −109.33) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 348.29 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-propylpyridinium thiocyanate* (***20***). It was obtained as yellow crystals; mp: 160--161 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.91--0.96 (m, 3H, C**H**~3~), 1.96--2.05 (m, 2H, NCH~2~C**H**~2~), 4.68 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.24 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.42 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.55 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.24 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.32 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 12.50 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 10.20 (**C**H~3~), 25.04, 24.12 (NCH~2~***C***H~2~), 62.28, 62.36 (N**C**H~2~), 115.76, 115.95, 116.16, 126.15, 127.13, 129.35, 129.44, 129.65, 129.72, 129.81, 130.02, 130.05, 130.22, 130.25, 145.10, 145.67, 147.40, 149.36, 149.66 (Ar--**C**), 158.79, 161.96, 162.27, 164.42, 164.74, 165.19 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.83), (−109.41 to −109.33) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 344.48 \[M^+^\].

*1-Butyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridinium hexafluorophosphate* (***21***). It was obtained as yellow crystals; mp: 145--146 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.91--0.96 (m, 3H, C**H**~3~), 1.28--1.39 (m, 2H, C**H**~2~CH~3~), 1.91--2.00 (m, 2H, NCH~2~C**H**~2~), 4.70 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.26 (t, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 8.15 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.24 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.46 (s, 0.75H, CON**H**), 12.51 (s, 0.25H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.27, 13.30 (**C**H~3~), 18.73, 18.80 (**C**H~2~CH~3~), 32.48, 32.57 (NCH~2~***C***H~2~), 60.79 (N**C**H~2~), 115.77, 115.96, 116.18, 126.16, 127.13, 129.35, 129.44, 129.73, 129.82, 130.05, 130.20, 130.23, 145.08, 145.69, 147.33, 149.34 (Ar--**C**), 158.76, 162.28, 164.76, 165.21 (**C**=N, **C**=O). ^31^P NMR (162 MHz, DMSO-*d*~6~): δ~P~ = −152.98 to −135.42 (m, 1P, **P**F~6~). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = −71.09, −69.19 (2s, 6F, P**F~6~**), (−109.88 to −109.84), (−109.41 to −109.33) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 445.02 \[M^+^\].

*1-Butyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridiniumtetrafluoroborate* (***22***). It was obtained as yellow crystals; mp: 172--173 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.92--0.97 (m, 3H, C**H**~3~), 1.28--1.39 (m, 2H, C**H**~2~CH~3~), 1.92--2.01 (m, 2H, NCH~2~C**H**~2~), 4.71 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.27 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.38 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.90 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.41 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 8.51 (s, 0.75H, **H**--C=N), 8.55 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.27 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.36 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 12.49 (s, 0.75H, CON**H**), 12.53 (s, 0.25H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 11.76 (**C**H~3~), 17.20, 17.27 (**C**H~2~CH~3~), 30.96, 31.06 (NCH~2~**C**H~2~), 59.19, 59.24 (N**C**H~2~), 114.25, 114.44, 114.66, 124.62, 125.59, 127.84, 127.93, 128.20, 128.29, 128.50, 128.66, 128.69, 143.54, 144.17, 145.75, 147.79, 148.07 (Ar--**C**), 157.23, 160.41, 160.74, 163.21, 164.68 (**C**=N, **C**=O). ^11^B NMR (128 MHz, DMSO-*d*~6~): δ~B~ = −1.29 (d, 1B, **B**F~4~). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.81), (−109.40 to −109.33) (2m, 1F, Ar--**F**); −148.22, −148.16 (2d, 4F, B**F**~4~). MS (ES) *m*/*z* = 387.27 \[M^+^\].

*1-Butyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridinium trifluoroacetate* (***23***). It was obtained as yellow crystals; mp: 178--179 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.91--0.96 (m, 3H, C**H**~3~), 1.28--1.37 (m, 2H, C**H**~2~CH~3~), 1.92--2.01 (m, 2H, NCH~2~C**H**~2~), 4.71 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.25 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.36 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.88 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.51 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.27 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.36 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.45 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.26, 13.28 (**C**H~3~), 18.71, 18.78 (**C**H~2~CH~3~), 32.45, 32.55 (NCH~2~**C**H~2~), 60.75, 60.79 (N**C**H~2~), 115.76, 115.94, 116.16, 126.14, 127.12, 129.38, 129.47, 129.72, 129.81, 130.01, 130.21, 130.24, 145.11, 145.70, 147.31, 149.40, 149.62 (Ar--**C**), 158.93, 161.95, 162.27, 164.42, 164.74, 165.14 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = −73.47 (s, 3F, C**F~3~**), (−109.87 to −109.81), (−109.40 to −109.32) (2m, 1F, Ar--**F**). MS (ESI) *m*/*z* = 414.00 \[M^+^ + H\].

*1-Butyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridinium nitrate **(24)***. It was obtained as yellow crystals; mp: 170--171 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.92--0.97 (m, 3H, C**H**~3~), 1.29--1.38 (m, 2H, C**H**~2~CH~3~), 1.92--2.02 (m, 2H, NCH~2~C**H**~2~), 4.71 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.27 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.38 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.90 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.17 (s, 0.25H, **H**--C=N), 8.41 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 8.52 (s, 0.75H, **H**--C=N), 8.55 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.28 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.36 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 12.49 (s, 0.75H, CON**H**), 12.53 (s, 0.25H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 15.03, 15.06 (**C**H~3~), 20.47, 20.53 (**C**H~2~CH~3~), 34.22, 34.32 (NCH~2~**C**H~2~), 62.46, 62.51 (N**C**H~2~), 117.52, 117.71, 117.93, 127.89, 128.86, 131.12, 131.20, 131.47, 131.56, 131.77, 131.93, 131.96, 146.81, 147.44, 149.02, 151.06, 151.34 (Ar--**C**), 160.50, 163.68, 164.01, 166.15, 166.48, 166.94 (**C**=N, **C**=O).^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.81), (−109.40 to −109.33) (2m, 1F, Ar--**F**). MS (ESI) *m*/*z* = 362.27 \[M^+^\].

*1-Butyl-4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)pyridinium thiocyanate* (***25***). It was obtained as yellow crystals; mp: 172--173 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.92−0.96 (m, 3H, C**H**~3~), 1.28−1.37 (m, 2H, C**H**~2~CH~3~), 1.92−2.01 (m, 2H, NCH~2~C**H**~2~), 4.72 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.24 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.38 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.41 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.51 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 9.27 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.36 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.49 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.46, 13.48 (**C**H~3~), 18.89, 18.96 (**C**H~2~CH~3~), 32.65, 32.74 (NCH~2~**C**H~2~), 60.88, 60.94 (N**C**H~2~), 115.94, 116.13, 116.35, 126.32, 127.29, 129.53, 129.62, 129.90, 129.99, 130.20, 130.36, 130.39, 145.24, 145.87, 147.46, 149.49, 149.77 (Ar--**C**), 158.93, 162.44, 164.91, 165.38 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.88 to −109.84), (−109.41 to −109.33) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 358.26 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-pentylpyridinium hexafluorophosphate* (***26***). It was obtained as yellow crystals; mp: 195--196 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.86−0.91 (m, 3H, C**H**~3~), 1.23−1.37 (m, 4H, 2×C**H**~2~), 1.93--2.02 (m, 2H, NCH~2~C**H**~2~), 4.69 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.23 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.37 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 8.15 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.24 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.46 (s, 0.75H, CON**H**), 12.51 (s, 0.25H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.69 (**C**H~3~), 21.50, 27.47, 27.55 (2×***C***H~2~), 30.20, 30.31 (NCH~2~**C**H~2~), 60.92, 61.00 (N**C**H~2~), 115.76, 115.96, 116.18, 126.16, 127.12, 129.34, 129.43, 129.73, 129.81, 130.20, 130.23, 145.09, 145.69, 147.34, 149.34 (Ar--**C**), 158.76, 162.28, 164.76, 165.22 (**C**=N, **C**=O).^31^P NMR (162 MHz, DMSO-*d*~6~): δ~P~ = −152.98 to −135.42 (m, 1P, **P**F~6~). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = −69.21, −71.10 (2s, 6F, P**F~6~**), (−109.89 to −109.81), (−109.41 to −109.34) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 459.90 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-pentylpyridinium tetrafluoroborate* (***27***). It was obtained as yellow crystals; mp: 205--206 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.86--0.90 (m, 3H, C**H**~3~), 1.23--1.37 (m, 4H, 2×C**H**~2~), 1.93--2.00 (m, 2H, NCH~2~C**H**~2~), 4.68 (t, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.23 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.37 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.15 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.34 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.47 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.70 (**C**H~3~), 21.51, 27.47, 27.55 (2×**C**H~2~), 30.20, 30.31 (NCH~2~**C**H~2~), 60.99 (N**C**H~2~), 115.76, 115.96, 116.18, 126.15, 127.11, 129.35, 129.44, 129.73, 129.82, 130.20, 130.23, 145.08, 145.68, 147.32, 149.33, 149.63(Ar--**C**), 158.76, 162.28, 164.75, 165.22 (**C**=N, **C**=O).^11^B NMR (128 MHz, DMSO-*d*~6~): δ~B~ = −1.29 (d, 1B, **B**F~4~). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.81), (−109.42 to −109.34) (2m, 1F, Ar--**F**); −148.28, −148.23 (2d, 4F, B**F**~4~). MS (ES) *m*/*z* = 401.00 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-pentylpyridinium trifluoroacetate* (***28***). It was obtained as yellow crystals; mp: 201--202 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.86--0.90 (m, 3H, C**H**~3~), 1.23--1.37 (m, 4H, 2×C**H**~2~), 1.93--2.00 (m, 2H, NCH~2~C***H***~2~), 4.68 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.23 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.37 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.15 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.34 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.48 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.70, 13.72 (**C**H~3~), 21.51, 27.47, 27.55 (2×**C**H~2~), 30.20, 30.31 (NCH~2~**C**H~2~), 60.92, 60.99 (N**C**H~2~), 115.76, 115.96, 116.18, 126.15, 127.11, 129.35, 129.44, 129.73, 129.81, 130.21, 130.24, 145.08, 145.69, 147.34, 149.33 (Ar--**C**), 158.77, 162.28, 164.75, 165.22 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = −73.50 (s, 3F, C**F~3~**), (−109.87 to −109.83), (−109.42 to −109.35) (2m, 1F, Ar--**F**). MS (ESI) *m*/*z* = 428.00 \[M^+^ + H\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-pentylpyridinium nitrate* (***29***). It was obtained as yellow crystals; mp: 200--201 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.86--0.90 (m, 3H, C**H**~3~), 1.23--1.37 (m, 4H, 2×C**H**~2~), 1.93--2.00 (m, 2H, NCH~2~C**H**~2~), 4.68 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.23 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.37 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.15 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.34 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.47 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.70, 1371 (**C**H~3~), 21.51, 24.47, 27.55 (2×***C***H~2~), 30.20, 30.31 (NCH~2~***C***H~2~), 60.91, 60.99 (N**C**H~2~), 115.76, 115.97, 116.19, 126.15, 127.12, 129.35, 129.44, 129.73, 129.82, 130.20, 130.23, 145.08, 145.69, 147.33, 149.33 (Ar--**C**), 158.76, 162.28, 164.75, 165.22 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.81), (−109.42 to −109.34) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 376.70 \[M^+^\].

*4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)-1-pentylpyridinium thiocyanate* (***30***). It was obtained as yellow crystals; mp: 197--198 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.86--0.90 (m, 3H, C**H**~3~), 1.23--1.37 (m, 4H, 2×C**H**~2~), 1.93--2.00 (m, 2H, NCH~2~C**H**~2~), 4.68 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.23 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.37 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.15 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.34 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.47 (s, 0.75H, CON**H**), 12.51 (s, 0.25H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.70, 1371 (**C**H~3~), 21.51, 27.47, 27.55 (2×**C**H~2~), 30.20, 30.31 (NCH~2~**C**H~2~), 60.92, 61.00 (N**C**H~2~), 115.76, 115.96, 116.18, 126.15, 127.12, 129.36, 129.44, 129.73, 129.82, 130..02, 130.20, 130.23, 145.08, 145.69, 147.32, 149.34, 149.63(Ar--**C**), 158.76, 162.28, 164.75, 165.21 (**C**=N, **C**=O).^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.89 to −109.81), (−109.42 to −109.34) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 372.00 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-hexylpyridinium hexafluorophosphate* (***31***). It was obtained as yellow crystals; mp: 143--144 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.86--0.93 (m, 3H, C**H**~3~), 1.28--1.34 (m, 6H, 3×C**H**~2~), 1.94--2.00 (m, 2H, NCH~2~C***H***~2~), 4.69 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.25 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.37 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 9.24 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.31 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 12.49 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.74, 13.76 (**C**H~3~), 21.80, 25.01, 25.04, 30.50, 30.58 (4×**C**H~2~), 60.96, 61.04 (N**C**H~2~), 115.73, 115.94, 116.16, 126.15, 127.14, 129.33, 129.42, 129.72, 129.80, 130.06, 130.20, 130.25, 145.04, 145.12, 145.65, 147.40, 149.37, 149.65 (Ar--**C**), 158.77, 161.96, 162.28, 164.43, 164.76, 165.20 (**C**=N, **C**=O). ^31^P NMR (162 MHz, DMSO-*d*~6~) δ~P~ = −157.37 to −131.02 (m, 1P, **P**F~6~). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = −71.10, −69.22 (2s, 6F, P**F~6~**), (−109.90 to −109.82), (−109.44 to −109.36) (2m, 1F, Ar--F). MS (ES) *m*/*z* = 473.39 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-hexylpyridinium tetrafluoroborate* (***32***). It was obtained as yellow crystals; mp: 204--205 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.86--0.92 (m, 3H, C**H**~3~), 1.29--1.30 (m, 6H, 3×C**H**~2~), 1.94--2.00 (m, 2H, NCH~2~C**H**~2~), 4.68 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.23 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.48 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.70, 13.72 (**C**H~3~), 21.75, 24.95, 24.99, 30.40, 30.45, 30.53 (4×**C**H~2~), 60.89, 60.97 (N**C**H~2~), 115.69, 115.89, 116.11, 126.09, 127.07, 129.29, 129.38, 129.66, 129.75, 129.98, 130.17, 130.20, 145.01, 145.61, 147.34, 149.31, 149.59 (Ar--**C**), 158.72, 162.22, 164.70, 165.15 (**C**=N, **C**=O). ^11^B NMR (128 MHz, DMSO-*d*~6~): δ~B~ = −1.28 (d, 1B, **B**F~4~). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.90 to −109.82), (−109.45 to −109.37) (2m, 1F, Ar--**F**); −148.30, −145.25 (2d, 4F, B**F**~4~). MS (ES) *m*/*z* = 415.22 \[M^+^\].

*4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)-1-hexylpyridinium trifluoroacetate* (***33***). It was obtained as yellow crystals; mp: 214--215 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.86--0.92 (m, 3H, C**H**~3~), 1.28--1.30 (m, 6H, 3×C**H**~2~), 1.94--2.00 (m, 2H, NCH~2~C**H**~2~), 4.68 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.23 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.50 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.76, 13.79 (**C**H~3~), 21.81, 25.01, 25.04, 30.50, 30.59 (4×**C**H~2~), 60.93, 61.00 (N**C**H~2~), 115.75, 115.96, 116.17, 126.14, 127.12, 129.35, 129.43, 129.71, 129.80, 130.03, 130.24, 130.27, 145.09, 145.66, 147.43, 149.34, 149.64 (Ar--**C**), 158.80, 162.27, 164.42, 164.74, 165.22 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = −73.50 (s, 3F, C**F~3~**), (−109.90 to −109.82), (−109.46 to −109.38) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 441.18 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-hexylpyridinium nitrate* (***34***). It was obtained as yellow crystals; mp: 214--215 °C^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.86--0.92 (m, 3H, C**H**~3~), 1.28--1.33 (m, 6H, 3×C**H**~2~), 1.94--2.00 (m, 2H, NCH~2~C**H**~2~), 4.70 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.26 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.17 (s, 0.25H, **H**--C=N), 8.41 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.51 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 9.27 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.36 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.50 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.76, 13.78 (**C**H~3~), 21.81, 25.01, 25.04, 30.46, 30.50, 30.59 (4×**C**H~2~), 60.93, 60.99 (N**C**H~2~), 115.75, 115.95, 116.17, 126.14, 127.12, 129.36, 129.45, 129.72, 129.80, 130.05, 130.23, 130.26, 145.08, 145.68, 147.37, 149.35, 149.62 (Ar--**C**), 158.78, 161.94, 162.26, 164.41, 164.73, 165.20 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.90 to −109.82), (−109.45 to −109.37) (2m, 1F, Ar--**F**). MS (ESI) *m*/*z* = 390.37 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-hexylpyridinium thiocyanate* (***35***). It was obtained as yellow crystals; mp: 189--190 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.86--0.92 (m, 3H, C**H**~3~), 1.28--1.33 (m, 6H, 3×C**H**~2~), 1.94--2.00 (m, 2H, NCH~2~C**H**~2~), 4.70 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.23 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.41 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.50 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.70, 13.72 (**C**H~3~), 21.75, 24.96, 24.99, 30.45, 30.54 (4×**C**H~2~), 60.89, 60.97 (N**C**H~2~), 115.69, 115.89, 116.11, 126.09, 127.07,129.29, 129.37, 129.52, 129.75, 130.00, 130.17, 130.20, 145.01, 145.61, 147.32, 149.29, 149.57 (Ar--**C**), 158.72,161.89, 162.21, 164.36, 164.69, 165.15 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.90 to −109.82), (−109.45 to −109.37) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 386.56 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-heptylpyridinium hexafluorophosphate* (***36***). It was obtained as yellow crystals; mp: 209--210 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.85--0.88 (m, 3H, C**H**~3~), 1.25--1.31 (m, 8H, 4×C**H**~2~), 1.91--2.00 (m, 2H, NCH~2~C**H**~2~), 4.69 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.23 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.35 (t, 1.5H, *J* = 8 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 8.51 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.34 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.49 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 13.87 (**C**H~3~), 21.91, 25.31, 25.36, 28.00, 30.51, 30.64, 30.96, 30.98 (5×**C**H~2~), 60.94, 61.01 (N**C**H~2~), 115.75, 115.96, 116.18, 126.14, 127.11, 126.36, 129.44, 129.73, 129.81, 130.05, 130.21, 130.24, 145.07, 145.67, 147.33, 149.34, 149.63 (Ar--**C**), 158.77, 162.28, 164.75, 165.22 (**C**=N, **C**=O). ^31^P NMR (162 MHz, DMSO-*d*~6~): δ~P~ = −157.37 to −131.02 (m, 1P, **P**F~6~). ^19^F NMR (377 MHz, DMSO-*d*~6~) δ~F~ = −71.10, −69.21 (2s, 6F, P**F~6~**), (−109.93 to −109.85), (−109.43 to −109.35) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 487.37 \[M^+^\].

*4-(2-(4-fluorobenzylidene)hydrazinecarbonyl)-1-heptylpyridinium tetrafluoroborate* (***37***). It was obtained as yellow crystals; mp: 203--204 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.85--0.89 (m, 3H, C**H**~3~), 1.25--1.31 (m, 8H, 4×C**H**~2~), 1.92--2.01 (m, 2H, NCH~2~C**H**~2~), 4.71 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.26 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.38 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.90 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.41 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.51 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 9.27 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.35 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 12.49 (s, 0.75H, CON**H**), 12.53 (s, 0.25H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 14.04 (**C**H~3~), 22.09, 25.47, 25.53, 28.17, 30.68, 30.81, 31.12, 31.15 (5×**C**H~2~), 61.09, 61.16 (N**C**H~2~), 115.92, 116.13, 116.35, 126.31, 127.27, 129.53, 129.62, 129.90, 129.99, 130.18, 130.35, 130.38, 145.23, 145.84, 147.43, 149.49, 149.77 (Ar--**C**), 158.93, 162.09, 162.43, 164.56, 164.91, 165.39 (**C**=N, **C**=O). ^11^B NMR (128 MHz, DMSO-*d*~6~): δ~B~ = −1.14 (d, 1B, **B**F~4~). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.76 to −109.69), (−109.25 to −109.17) (2m, 1F, Ar--**F**); −148.08, −148.03 (2d, 4F, B**F**~4~). MS (ES) *m*/*z* = 429.21 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-heptylpyridinium trifluoroacetate* (***38***). It was obtained as yellow crystals; mp: 203--204 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.85--0.88 (m, 3H, C**H**~3~), 1.23--1.31 (m, 8H, 4×C**H**~2~), 1.94--2.02 (m, 2H, NCH~2~C***H***~2~), 4.69 (dd, 2H, *J* = 4 Hz, 8 Hz, NC**H**~2~), 7.23 (t, 0.5H, *J* = 8 Hz, Ar--**H**), 7.38 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.62 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.89 (dd, 1.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 8.16 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.50 (s, 0.75H, **H**--C=N), 8.53 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 9.25 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.33 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 12.50 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 12.67 (**C**H~3~), 20.71, 24.11, 24.16, 26.08, 29.31, 29.44, 29.75, 29.78 (5×**C**H~2~), 59.71, 59.78 (N**C**H~2~), 114.54, 114.76, 114.98, 124.94, 125.90, 128.22, 128.51, 128.59, 128.85, 129.01, 129.04, 143.85, 144.46, 146.19, 148.09 (Ar--**C**), 157.59, 161.06, 163.53, 164.04 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = −73.48 (s, 3F, C**F~3~**), (−109.91 to −109.83), (−109.43 to −109.35) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 455.90 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-heptylpyridinium nitrate* (***39***). It was obtained as yellow crystals; mp: 204--205 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.85--0.89 (m, 3H, C**H**~3~), 1.24--1.32 (m, 8H, 4×C**H**~2~), 1.94--2.01 (m, 2H, NCH~2~C**H**~2~), 4.70 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.26 (dd, 0.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.38 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.90 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 8.17 (s, 0.25H, **H**--C=N), 8.41 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 8.52 (s, 0.75H, **H**--C=N), 8.55 (d, 1.5H, *J* = 8 Hz, Ar--**H**), 9.27 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 9.36 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 12.50 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 14.08 (**C**H~3~), 22.12, 25.51, 25.56, 28.20,30.72, 30.84, 31.16, 31.18 (5×**C**H~2~), 61.12, 61.18 (N**C**H~2~), 115.95, 116.16, 116.37, 126.34, 127.30, 129.57, 129.65, 129.93, 130.01, 130.21, 130.39, 130.42, 145.25, 145.88, 147.47, 149.51, 149.80 (Ar--**C**), 158.95, 162.12, 162.46, 164.93, 165.42 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.93 to −109.85), (−109.43 to −109.35) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 404.90 \[M^+^\].

*4-(2-(4-Fluorobenzylidene)hydrazinecarbonyl)-1-heptylpyridinium thiocyanate* (***40***). It was obtained as yellow crystals; mp: 175--176 °C. ^1^H NMR (400 MHz, DMSO-*d*~6~): δ~H~ = 0.85--0.89 (m, 3H, C**H**~3~), 1.25--1.32 (m, 8H, 4×C**H**~2~), 1.94--2.01 (m, 2H, NCH~2~C**H**~2~), 4.70 (t, 2H, *J* = 8 Hz, NC**H**~2~), 7.26 (dd, 0.5H, *J* = 8 Hz, 12 H, Ar--**H**), 7.38 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 7.63 (dd, 0.5H, *J* = 4 Hz, 8 Hz, Ar--**H**), 7.90 (dd, 1.5H, *J* = 8 Hz, 12 Hz, Ar--**H**), 8.17 (s, 0.25H, **H**--C=N), 8.40 (d, 0.5H, *J* = 4 Hz, Ar--**H**), 8.51 (s, 0.75H, **H**--C=N), 8.54 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 9.27 (d, 0.5H, *J* = 8 Hz, Ar--**H**), 9.35 (d, 1.5H, *J* = 4 Hz, Ar--**H**), 12.51 (bs, 1H, CON**H**). ^13^C NMR (100 MHz, DMSO-*d*~6~): δ~C~ = 14.02 (**C**H~3~), 22.07, 25.47, 28.52, 28.16, 30.69, 30.81, 31.11, 31.14 (5×**C**H~2~), 61.09, 61.17 (N**C**H~2~), 115.89, 116.10, 116.32, 126.30, 127.27, 129.51, 129.60, 129.88, 129.97, 130.16, 130.19, 130.34, 130.37, 145.21, 145.82, 147.42, 149.48, 149.75 (Ar--**C**), 158.91, 162.08, 162.41, 164.55, 164.89, 165.36 (**C**=N, **C**=O). ^19^F NMR (377 MHz, DMSO-*d*~6~): δ~F~ = (−109.93 to −109.85), (−109.43 to −109.35) (2m, 1F, Ar--**F**). MS (ES) *m*/*z* = 400.00 \[M^+^\].

3.5. Biological Activity {#sec3dot5-ijms-17-00766}
------------------------

### 3.5.1. Antimicrobial Activity {#sec3dot5dot1-ijms-17-00766}

#### Antimicrobial Evaluation Using the MIC Assay

The *in vitro* minimum inhibitory concentrations (MICs) of the antimicrobial activities were measured by the broth microdilution method \[[@B19-ijms-17-00766],[@B20-ijms-17-00766]\]. The tested pathogenic strains were provided by the Regional Center for Mycology and Biotechnology (RCMB).

#### Cell Lines

The synthesized compounds **5**--**40** were evaluated for their antimicrobial activity against *Streptococcus pneumonia* RCMB 010010, *Bacillus subtilis* RCMB 010067, *Staphylococcus aureus* RCMB 010025 (Gram-positive bacteria), *Pseudomonas aeuroginosa* RCMB 010043, *Escherichia coli* RCMB 010052, *Klebsiella pneumonia* RCMB 010058 (Gram-negative bacteria), *Aspergillus fumigates* RCMB 02568 and *Candida albicans* RCMB 05036 (Fungi). The tested compounds (10 mg) were dissolved in dimethylsulfoxide (DMSO, 1 mL) and then diluted in culture medium (Mueller-Hinton Broth for bacteria and Sabouraud Liquid Medium for fungi) with further progressive dilutions to obtain final concentrations of 1, 2, 4, 8, 16, 31.25, 62.5, 125, 250 and 500 mg·mL^−1^. The DMSO content never exceeded 1% *v*/*v*. The tubes were inoculated with 105 cfu·mL^−1^ (colony forming units/mL) and incubated at 37 °C for 24 h. Growth controls consisting of media and media with DMSO at the same dilutions as used in the experiments were employed.

### 3.5.2. Anticancer Activity {#sec3dot5dot2-ijms-17-00766}

#### Cell Lines

Human breast adenocarcinoma MCF-7, human ductal breast epithelial tumor T47D, human epithelial carcinoma Hela and human epithelial colorectal adenocarcinoma Caco-2 were cultivated in Dulbecco's modified Eagle medium (DMEM, Biochrom, Berlin, Germany). All cell lines were cultured at 37 °C, and all media were supplemented with 1% 2 mM [l]{.smallcaps}-glutamine (Lonza), 10% fetal calf serum (Gibco, Paisley, UK), 50 IU/mL penicillin/streptomycin (Sigma, St. Louis, MO, USA) and amphotericin B (Sigma, St. Louis, MO, USA). For the cytotoxicity test, each examined compound was added to the culture medium and incubated for 48 h in an atmosphere of 5% CO~2~ and 95% relative humidity at 37 °C.

#### Cytotoxicity Evaluation Using the MTT Assay

The cytotoxic effects associated with the examined compounds were evaluated according to the protocol described in ISO 10993-5 \[[@B21-ijms-17-00766]\]. Cells were seeded at a density of 8 × 10^3^ cells per well in 96-well plates in the appropriate medium. In all assays, the drugs were dissolved in DMSO immediately before the addition to the cell cultures, and an equal amount of solvent was added to control the cells. At the end of the exposure period, the MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide) (Sigma-Aldrich, Dorset, UK) assay was carried out as previously described (ISO, 2009). The yellow tetrazolium dye of MTT was reduced by metabolically active cells into an intracellular purple formazan product. The absorbance values of each well were determined with a microplate enzyme-linked immuno-assay (ELISA) reader equipped with a 570-nm filter. The survival rates of the controls were set to represent 100% viability. Untreated cultures were used as the control groups.

4. Conclusions {#sec4-ijms-17-00766}
==============

The synthesis of fluorinated pyridinium-based hydrazones **5--10** was successfully achieved through the alkylation of *N*-(4-fluorobenzylidene)isonicotinohydrazide (3) with the appropriate alkyl iodides under both conventional and ultrasound conditions. The ultrasound-assisted metathetic synthesis has also been investigated and gave the desired **11--40**. A comparison of the results from using US with that under the classical method revealed an improvement in the reaction yields and a reduction in the reaction time. Most of the synthesized compounds showed good to excellent antibacterial activity at MIC 4--16 µg/ml, whereas only **12**, **23**, **31--33** and **36--38** were found active against fungal strains at MIC 8--16 µg/ml. On the other hand, the tested **5**, **12** and **14** showed significant antiproliferative activity against four different human cancerous cell lines at moderate doses.

###### 

Click here for additional data file.

Supplementary materials can be found at <http://www.mdpi.com/1422-0067/17/5/766/s1>.
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![Synthesis of halogenated pyridinium salts tagged with hydrazone **5**--**10** under conventional method (CM) and ultrasound irradiation (US).](ijms-17-00766-sch001){#ijms-17-00766-sch001}

![^1^H NMR spectrum of compound **9** in DMSO-*d*~6~.](ijms-17-00766-g001){#ijms-17-00766-f001}

![^1^H NMR spectrum of compound **9** in CDCl~3~.](ijms-17-00766-g002){#ijms-17-00766-f002}

![^19^F NMR spectrum of compound **9** in DMSO-*d*~6~.](ijms-17-00766-g003){#ijms-17-00766-f003}

![Synthesis of specific-based hydrazones **11**--**40**.](ijms-17-00766-sch002){#ijms-17-00766-sch002}

ijms-17-00766-t001_Table 1

###### 

Conventional *versus* ultrasound times and yields of hydrazone **3** and pyridinium salts **5**--**10**.

  ---------------------------------------------------------------------------------
  Compound No.   R           Conventional Method\   Ultrasound Method\         
                             CM                     US                         
  -------------- ----------- ---------------------- -------------------- ----- ----
  **3**          --          1                      90                   0.5   96

  **5**          C~2~H~5~    72                     85                   12    94

  **6**          C~3~H~7~    72                     83                   12    93

  **7**          C~4~H~9~    72                     85                   14    90

  **8**          C~5~H~11~   72                     91                   14    94

  **9**          C~6~H~13~   72                     86                   14    92

  **10**         C~7~H~15~   72                     91                   14    94
  ---------------------------------------------------------------------------------

ijms-17-00766-t002_Table 2

###### 

Conventional *versus* ultrasound times and yields of compounds **11**--**40**.

  ------------------------------------------------------------------------------------------
  Compound No.   R           Y          Conventional Method\   Ultrasound Method\       
                                        CM                     US                       
  -------------- ----------- ---------- ---------------------- -------------------- --- ----
  **11**         C~2~H~5~    PF~6~      16                     94                   6   98

  **12**         C~2~H~5~    BF~4~      16                     85                   6   92

  **13**         C~2~H~5~    COOCF~3~   16                     80                   6   90

  **14**         C~2~H~5~    NO~3~      16                     89                   5   98

  **15**         C~2~H~5~    SCN        16                     98                   6   98

  **16**         C~3~H~7~    PF~6~      16                     93                   6   96

  **17**         C~3~H~7~    BF~4~      16                     81                   6   90

  **18**         C~3~H~7~    COOCF~3~   16                     85                   6   94

  **19**         C~3~H~7~    NO~3~      16                     82                   5   92

  **20**         C~3~H~7~    SCN        16                     85                   5   96

  **21**         C~4~H~9~    PF~6~      16                     88                   6   94

  **22**         C~4~H~9~    BF~4~      16                     83                   6   90

  **23**         C~4~H~9~    COOCF~3~   16                     85                   6   92

  **24**         C~4~H~9~    NO~3~      16                     83                   5   90

  **25**         C~4~H~9~    SCN        16                     83                   5   92

  **26**         C~5~H~11~   PF~6~      16                     86                   6   94

  **27**         C~5~H~11~   BF~4~      16                     90                   6   98

  **28**         C~5~H~11~   COOCF~3~   16                     80                   6   92

  **29**         C~5~H~11~   NO~3~      16                     94                   5   98

  **30**         C~5~H~11~   SCN        16                     96                   5   98

  **31**         C~6~H~13~   PF~6~      16                     91                   6   98

  **32**         C~6~H~13~   BF~4~      16                     98                   6   98

  **33**         C~6~H~13~   COOCF~3~   16                     89                   6   92

  **34**         C~6~H~13~   NO~3~      16                     87                   5   94

  **35**         C~6~H~13~   SCN        16                     98                   5   98

  **36**         C~7~H~15~   PF~6~      16                     98                   6   98

  **37**         C~7~H~15~   BF~4~      16                     98                   6   98

  **38**         C~7~H~15~   COOCF~3~   16                     80                   6   88

  **39**         C~7~H~15~   NO~3~      16                     83                   6   88

  **40**         C~7~H~15~   SCN        16                     80                   6   86
  ------------------------------------------------------------------------------------------
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###### 

Antimicrobial activity expressed as MIC (μg/mL).

  Compound No.        Gram-Positive Organisms   Gram-Negative Organisms   Fungi                          
  ------------------- ------------------------- ------------------------- ------- ---- ---- ---- ------- -------
  **5**               16                        16                        16      16   16   16   125     125
  **7**               16                        16                        16      16   16   16   62.5    125
  **9**               8                         8                         16      16   8    8    62.5    62.5
  **10**              8                         8                         8       16   8    8    62.5    62.5
  **11**              8                         4                         4       8    8    8    31.25   31.25
  **12**              8                         4                         8       4    8    8    16      16
  **13**              4                         4                         8       16   16   16   31.25   31.25
  **14**              16                        16                        16      16   16   16   125     125
  **15**              16                        16                        16      16   16   16   250     250
  **21**              8                         4                         4       8    8    8    31.25   31.25
  **22**              8                         4                         4       4    8    8    31.25   31.25
  **23**              4                         4                         8       8    8    8    16      16
  **24**              16                        16                        16      16   16   16   125     125
  **25**              16                        16                        16      16   16   16   125     125
  **31**              8                         8                         4       8    8    8    16      16
  **32**              4                         4                         4       8    4    4    16      16
  **33**              4                         4                         4       4    4    4    8       8
  **34**              8                         8                         8       8    4    8    125     125
  **35**              8                         8                         8       8    4    8    125     125
  **36**              4                         4                         4       4    4    4    16      16
  **37**              4                         4                         4       4    4    4    8       8
  **38**              4                         4                         4       4    4    4    8       8
  **39**              4                         4                         8       4    4    8    125     125
  **40**              4                         4                         8       4    4    8    125     125
  **Ciprofloxacin**   ≤5                        ≤1                        ≤5      ≤5   ≤1   ≤1   --      --
  **Fluconazole**     --                        --                        --      --   --   --   ≤1      ≤1
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###### 

LD~50~ values (ng/µL) of the examined compounds on four human cancer cell lines. Values are expressed as the mean ± SD of three experiments.

  Compound No.   MCF-7        T47D         HeLa         Caco-2
  -------------- ------------ ------------ ------------ ------------
  **5**          286 ± 8      278 ± 10     292 ± 9      301 ± 11
  **11**         Not active   Not active   Not active   Not active
  **12**         512 ± 11     498 ± 6      503 ± 8      528 ± 10
  **13**         Not active   Not active   Not active   Not active
  **14**         465 ± 8      486 ± 13     471 ± 15     463 ± 9
  **15**         Not active   Not active   Not active   Not active

Human ductal breast epithelial tumor **T47D**; Human breast adenocarcinoma **MCF-7**; Human epithelial carcinoma **HeLa**; Human epithelial colorectal adenocarcinoma **Caco-2**.
